Comprehensive medication guide to Ubrelvy including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0/month for eligible commercially insured patients using the Ubrelvy Complete Savings Card; standard copay varies $30–$150 depending on plan tier. Most plans require prior authorization and step therapy. Medicare Part D coverage varies by plan.
Estimated Cash Pricing
$1,139 list price per 30-day supply; $1,300–$1,450 retail for 10 tablets without insurance; as low as $970–$1,050 with GoodRx or SingleCare discount coupons. No generic available.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Ubrelvy (ubrogepant) is a prescription brand-name tablet used for the acute treatment of migraine with or without aura in adults. It received FDA approval on December 23, 2019, making it the first oral CGRP receptor antagonist (gepant) approved for acute migraine treatment. It is manufactured by AbbVie (originally developed by Allergan).
Ubrelvy belongs to a class called CGRP receptor antagonists, also known as "gepants." It is taken at the first sign of a migraine attack — not daily as a preventive medication. A second dose may be taken at least 2 hours after the initial dose if needed, with a maximum of 200 mg in 24 hours. The safety of treating more than 8 migraines per 30-day period has not been established.
No generic version of Ubrelvy is currently available, and one is not expected until at least 2035 due to patent protections. Ubrelvy is not a controlled substance and can be prescribed by any licensed provider, including via telehealth.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
During a migraine attack, the brain releases a protein called calcitonin gene-related peptide (CGRP). CGRP binds to receptors on sensory nerve endings and triggers vasodilation (blood vessel dilation), neurogenic inflammation, and pain signal amplification — all of which contribute to the characteristic throbbing headache, nausea, and light/sound sensitivity of a migraine.
Ubrogepant (the active molecule in Ubrelvy) is a highly potent, orally administered CGRP receptor antagonist. It binds to the CGRP receptor, blocking CGRP from attaching and initiating the pain cascade. By occupying the receptor without activating it, Ubrelvy interrupts migraine signaling at a fundamental molecular level — without causing blood vessel constriction.
This mechanism distinguishes Ubrelvy from triptans (which constrict blood vessels) and makes it safe for patients with cardiovascular conditions that contraindicate triptan use. In pivotal trials (ACHIEVE I and II), Ubrelvy achieved significantly higher rates of 2-hour pain freedom and most-bothersome-symptom relief compared to placebo across 1,439 adult migraine patients.
50 mg — tablet
Standard starting dose; may take second 50 mg dose at least 2 hours after first if needed
100 mg — tablet
Higher dose option; may take second 100 mg dose at least 2 hours after first if needed; max 200 mg per 24 hours
Ubrelvy is not listed on the FDA's Drug Shortages database in 2026 — AbbVie is actively manufacturing and distributing it. However, many patients still experience real difficulty filling their prescription. The main barriers are cost (no generic, $1,100+ per month list price), insurance prior authorization and step therapy requirements, and inconsistent pharmacy stocking at retail chains.
Not all pharmacies routinely stock Ubrelvy — particularly in smaller markets. Its unit-dose packaging and high cost make it a low-priority inventory item for some chains. Independent pharmacies and mail-order services tend to be more reliable for consistent access.
The fastest way to find Ubrelvy in stock is to use medfinder, which calls pharmacies near you to identify who can fill your prescription and texts you the results. This eliminates the need to call pharmacy after pharmacy yourself.
Because Ubrelvy is not a controlled substance, it can be prescribed by any licensed healthcare provider without special DEA registration. There are no prescriber restrictions unique to ubrogepant beyond standard prescribing authority for a given state license.
Neurologists and headache specialists (most commonly for complex or refractory migraine)
Primary care physicians (family medicine, internal medicine)
OB/GYNs (migraine is common in women; OB/GYNs often manage menstrual migraine)
Nurse practitioners (NPs) and physician assistants (PAs) — full prescribing authority for non-controlled substances in most states
Ubrelvy is available through telehealth platforms as well. Since it is not a controlled substance, providers can prescribe it via virtual consultation without an in-person visit. Platforms offering migraine consultations include Teladoc, Thirty Madison's Cove, and others. Note: some insurance plans (particularly VA criteria for use) may require initiation by a neurologist or headache specialist.
No. Ubrelvy (ubrogepant) is not a controlled substance. It has no DEA scheduling, no abuse or addiction potential, and does not require a special prescription format or DEA-licensed prescriber. There are no restrictions on the number of refills beyond standard pharmacy and insurance policies.
This also means Ubrelvy can be prescribed via telehealth without any special requirements. Any licensed prescriber — including primary care physicians, nurse practitioners, and physician assistants — can write a prescription for Ubrelvy. It is not a narcotic and carries no driving restriction specific to its controlled substance classification (though patients should be aware that somnolence is a reported side effect and caution is appropriate if drowsiness occurs).
Ubrelvy has a favorable side effect profile compared to many other migraine medications. The most commonly reported side effects from clinical trials are:
Nausea (4% of patients)
Sleepiness / somnolence (3%)
Dry mouth (post-marketing reports)
Severe allergic reactions (hypersensitivity): Anaphylaxis, dyspnea, facial/throat edema have been reported. Seek emergency care immediately if these occur.
New or worsening hypertension: Can occur at any time; most often within 7 days of starting therapy. Blood pressure check recommended 2–4 weeks after initiation.
Raynaud's phenomenon: New-onset or worsening circulation problems in fingers/toes reported. Discontinue if symptoms develop.
Know what you need? Skip the search.
Nurtec ODT (rimegepant)
Same CGRP class as Ubrelvy; orally dissolving tablet (75 mg); also FDA-approved for prevention of episodic migraine; cannot re-dose within 24 hours
Zavzpret (zavegepant)
Intranasal CGRP antagonist (10 mg spray); fastest onset among gepants; useful for patients with nausea or vomiting
Sumatriptan (generic Imitrex)
Generic triptan; highly effective; $10–$30 for 9 tablets with discount; causes vasoconstriction — contraindicated with cardiovascular disease
Rizatriptan (generic Maxalt)
Generic triptan; available as ODT; fast-acting; $15–$40 for 9 tablets; same cardiovascular contraindications as sumatriptan
Prefer Ubrelvy? We can find it.
Ketoconazole / Itraconazole
majorStrong CYP3A4 inhibitors — contraindicated with Ubrelvy. Can increase ubrogepant exposure up to 9.7-fold.
Clarithromycin
majorStrong CYP3A4 inhibitor — contraindicated with Ubrelvy. Common antibiotic used for respiratory infections.
Nirmatrelvir/ritonavir (Paxlovid)
majorStrong CYP3A4 inhibitor — contraindicated. Tell prescriber you take Ubrelvy before starting Paxlovid for COVID-19.
Verapamil / Diltiazem
moderateModerate CYP3A4 inhibitors — dose reduction to max 50 mg Ubrelvy per day required with concomitant use.
St. John's Wort
moderateCYP3A4 inducer — reduces Ubrelvy effectiveness. Avoid combining or discuss with doctor.
Rifampin
majorStrong CYP3A4 inducer — reduces ubrogepant exposure by approximately 80%. Avoid combination.
Grapefruit / grapefruit juice
moderateCYP3A4 inhibitor via food — dose modification recommended. Avoid second dose within 24 hours of consuming grapefruit.
Ubrelvy (ubrogepant) represents a meaningful advance in acute migraine treatment. As the first oral CGRP antagonist approved for this purpose, it offers effective, non-vasoconstrictive relief — making it particularly valuable for patients who cannot tolerate or use triptans. Its ability to be re-dosed after 2 hours, taken with or without food, and used at any stage of a migraine attack adds practical flexibility.
The primary challenges for patients in 2026 are cost (no generic, $1,100+ list price) and insurance coverage barriers (prior authorization, step therapy). The AbbVie savings card and patient assistance programs can dramatically reduce cost for eligible patients. Working with your doctor to navigate prior authorization is the most important step toward making Ubrelvy financially accessible.
If you've addressed the cost and coverage barriers but still can't find Ubrelvy at your local pharmacy, medfinder can help you quickly locate which pharmacies near you have it in stock — saving the time and frustration of calling pharmacy after pharmacy during a migraine flare.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini